Special Drug-Use Results Survey of IMBRUVICA Capsules 140 mg (relapsed or refractory mantle cell lymphoma [MCL])

Trial Profile

Special Drug-Use Results Survey of IMBRUVICA Capsules 140 mg (relapsed or refractory mantle cell lymphoma [MCL])

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Janssen Pharmaceutical KK
  • Most Recent Events

    • 10 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top